
A real-world study of 148 patients with severe CRSwNP found that extending dupilumab dosing to every four weeks did not compromise treatment outcomes over two years. Symptom improvements were significant in both standard (biweekly) and extended (monthly) dosing groups. No differences were observed in polyp volume, nasal obstruction, quality of life, or olfaction. Findings support safe dose de-escalation in select patients.
Like
Save
Share